AMRI Relocates Bothell R&D Facility

Laboratory Capacity Expanded to Support Demand for R&D Services
ALBANY, N.Y.--(Business Wire)--
AMRI (NASDAQ: AMRI) today announced that it has completed the relocation of its
Bothell, Washington research unit into approximately 44,000 square feet of
nearby newly refurbished laboratory and office space. Besides substantial
improvements in operational efficiencies gained by consolidating all staff and
services into one building, the new site provides capacity for growth, currently
projected to be double the scale of the current operation over the next five
years.

This investment demonstrates the company`s continued commitment to providing
high end technology focused on pharmaceutical lead discovery and optimization
for customers as well as for AMRI`s own internal drug discovery programs. The
new Bothell facility is equipped to support future enhancements encompassing
early biology and natural product drug discovery capabilities, furthering the
company`s ability to provide scientific services across a fully integrated drug
discovery, development and manufacturing platform.

"We are pleased to announce the successful completion of this move that
simultaneously positions us to continue to realize margin growth by executing on
plans that provide significant cost savings, but that also sets the stage for
future growth," said Chairman, CEO and President Thomas E. D`Ambra, Ph.D. "In
this current business climate, we believe the pharmaceutical industry will
continue to be challenged to simultaneously contain costs while continuing to
populate new drug pipelines, resulting in an increased demand for outsourcing
services."

About AMRI

Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific
services, products and technologies focused on improving the quality of life.
AMRI works on drug discovery and development projects and conducts manufacturing
of active ingredients and pharmaceutical intermediates for many of the world's
leading healthcare companies. As an additional value added service to its
customers, the company is also investing in R&D in order to expand its contract
services and to identify novel early stage drug candidates with the goal to
outlicense to a strategic partner. With locations in the U.S., Europe, and Asia,
AMRI provides customers with a wide range of services, technologies and cost
models.

Forward-Looking Statements

Statements in this press release that are not historical facts are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 that involve risks and uncertainties. These
statements may be identified by forward-looking words such as "may," "could,"
"should," "would," "will," "intend," "expect," "anticipate," "believe" and
"continue" or similar words and include, but are not limited to, statements by
AMRI`s Chairman, CEO and President and statements concerning the company`s plans
for its Bothell facilities, anticipated future capacity at such facilities and
the performance of the company`s global chemistry platform. Readers should not
place undue reliance on our forward-looking statements. The company's actual
results may differ materially from such forward-looking statements as a result
of numerous factors, some of which the company may not be able to predict and
may not be within the company's control. Factors that could cause such
differences include, but are not limited to the company's ability to attract and
retain experienced scientists, trends in pharmaceutical and biotechnology
companies outsourcing of chemical research and development, the company's
ability to enforce its intellectual property and technology rights, the risks
posed by international operations to the company, and the company's ability to
effectively manage its growth as well as those factors discussed in the
company's Annual Report on Form 10-K for the year ended December 31, 2008 as
filed with the Securities and Exchange Commission on March 13, 2009 and the
company's other SEC filings. The company does not undertake any duty to and does
not intend to update any forward-looking statements contained in this press
release after the date of this press release.

AMRI
Media
Corporate Communications
Andrea Schulz, 518-512-2226
or
Investors
Investor Relations
Peter Jerome, 518-512-2220

Copyright Business Wire 2009